Levocarnitine

左卡尼汀

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameLevocarnitine
Drug Alias Name肉酸Levocarnitinum左旋肉碱LevocarnitinaL-carnitine +[10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCarnitine acetylase stimulants
TargetsCarnitine acetylase
Therapy Area/IndicationsDiabetic peripheral neuropathyCarnitine deficiencySolid tumours +[34
Global Approved IndicationsCarnitine deficiencyDeficiency Diseases
Approved Indications in ChinaCarnitine deficiency
Original Approved Country/TerritoryUnited States
Original Approved Date1985/12/27
Country/TerritoryCanadaUnited StatesMexico +[10
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSigma-Tau Spa
China Registration ClassN/A

Develop Information

Active IndicationsDiabetic peripheral neuropathyCarnitine deficiencyDrug-Related Side Effects and Adverse Reactions +[19
Inactive IndicationsSolid tumoursPatient ComplianceFatigue +[15

Other Information

ATC CodeA16AA01